Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2001
11/14/2001CN1321503A Bitong capsule for treating numbness
11/14/2001CN1074665C Method and medical agent for diagnosis and/or therapy of arthritis
11/13/2001US6316502 Administering disulfide derivative of dithiocarbamate compound to bind to iron
11/13/2001US6316485 1,5-diphenylpyrazole derivatives
11/13/2001US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001US6316471 Treating inflammatory or autoimmune diseases
11/13/2001US6316466 Pyrazole derivatives P-38 MAP kinase inhibitors
11/13/2001US6316464 P38 MAP kinase inhibitors
11/13/2001US6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
11/13/2001US6316444 SRC kinase inhibitor compounds
11/13/2001US6316415 Sulfonamide interleukin-1β converting enzyme inhibitors
11/13/2001US6316217 Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same
11/13/2001US6316203 Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/13/2001US6316009 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharamaceutical and cosmetic compositions containing same
11/13/2001US6315998 Administering anti-cd40 monoclonal antibody or an antigen binding fragment which is being free of significant agonistic activity and binding to a human cd40 antigen located on surface of a human b cell prevents growth or differentiation
11/13/2001US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/13/2001CA2064793C Hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
11/08/2001WO2001083782A2 Novel proteases
11/08/2001WO2001083775A2 Proteases
11/08/2001WO2001083772A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001WO2001083698A2 Compositions and methods for inducing activation of dendritic cells
11/08/2001WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001WO2001083555A2 Pain signaling molecules
11/08/2001WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001WO2001083524A2 Rna metabolism proteins
11/08/2001WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001WO2001083510A1 29 human secreted proteins
11/08/2001WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001WO2001083484A1 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/08/2001WO2001083479A2 Process for the preparation of pyrazolopyridine derivatives
11/08/2001WO2001083475A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001WO2001083469A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001WO2001083427A1 PPARη MODULATORS
11/08/2001WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001WO2001082968A1 Cell proliferation inhibitors
11/08/2001WO2001082958A2 Methods of producing membrane vesicles
11/08/2001WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001WO2001082941A1 Composition for treatment of b-type hepatitis and liver cirrhosis
11/08/2001WO2001082940A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001WO2001082939A1 Treatment of conditions of the central nervous system using mycobacteria
11/08/2001WO2001082936A1 Use of fucoidin in the treatment of arthritis
11/08/2001WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001WO2001082897A2 Liposome drug delivery
11/08/2001WO2001082888A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001WO2001082720A1 Pet food composition for reducing inflammatory response in cats
11/08/2001WO2001068070A8 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
11/08/2001WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001WO2001049657A8 2-`3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
11/08/2001WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001WO2001037780A8 Urotensin-ii analogs
11/08/2001WO2001034180A3 Interferon gamma for the treatment of asthma
11/08/2001WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001WO2001030383A3 Medicament in order to induce tolerance
11/08/2001WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001WO2000033888A3 Prodrug compounds and process for preparation thereof
11/08/2001WO2000017133A3 Lta4 hydrolase inhibitors
11/08/2001US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001US20010039343 Pesticides, fungicides, herbicides, insecticides, microbiocdes, drugs
11/08/2001US20010039290 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor from cells
11/08/2001US20010039289 Antagonists; especially sodium salts
11/08/2001US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001US20010039026 Assay method
11/08/2001EP1144348A3 Lta 4? hydrolase inhibitors
11/08/2001DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001CA2408105A1 Novel proteases
11/08/2001CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001CA2407796A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001CA2407746A1 Proteases
11/08/2001CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001CA2407604A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001CA2407597A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001CA2407587A1 Ppar.gamma. modulators
11/08/2001CA2407435A1 Rna metabolism proteins
11/08/2001CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001CA2407399A1 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/08/2001CA2407334A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001CA2407294A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001CA2407225A1 Methods of producing membrane vesicles
11/08/2001CA2407219A1 Pain signaling molecules
11/08/2001CA2407136A1 Treatment of conditions of the central nervous system using mycobacteria
11/08/2001CA2405832A1 P-(sulfonyl)aryl and heteroaryls
11/08/2001CA2403901A1 29 human secreted proteins
11/08/2001CA2377629A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/07/2001EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
1 ... 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 ... 1272